The pharmaceutical industry faces a fundamental challenge: how to identify promising drug candidates faster, more reliably, and at lower cost. Traditional bioassay development—manual, labor-intensive, and often limited in scale—has become a bottleneck in the drug discovery pipeline. Automated bioassay development and high-throughput screening (HTS) are transforming this landscape, enabling researchers to test thousands to millions of compounds against biologically relevant targets in increasingly sophisticated model systems.

The convergence of advanced biosensor technologies, 3D cell models, artificial intelligence, and robotic automation is reshaping what is possible in early-stage drug discovery. This article examines the emerging trends and breakthrough discoveries defining the field in 2026. For related insights on pharmaceutical research, see Pharmaceutical Manufacturing 2025-2026: Key Research Trends, Digital Innovation, and Future Opportunities.

1. The Evolving HTS Landscape: From Simple Targets to Complex Biology

High-throughput screening has traditionally relied on reductionist approaches—testing compounds against isolated enzymes or simplified cell lines in 96- or 384-well formats. While productive, these methods often fail to predict systemic efficacy or complex toxicity in living organisms.

The field is now moving toward more physiologically relevant models. Patient-derived 3D cell models, including organoids and spheroids, are bridging the gap between traditional 2D cultures and in vivo models, making them attractive for increased-throughput screening (ITS) and secondary assays.

The Rise of Organoid-Based Screening

Organoids—self-organizing 3D structures derived from patient tissue or stem cells—offer several advantages for HTS. They recapitulate tumor architecture, cellular heterogeneity, and drug response patterns more faithfully than 2D cultures.

A 2026 review highlights that organoid-based ITS assays have been applied across multiple solid tumors, including pancreatic ductal adenocarcinoma, colorectal cancer, ovarian cancer, prostate cancer, non-small cell lung cancer, and neuroblastoma. In one notable study, 150,000 compounds were screened against PDAC organoids in 1536-well format, identifying 711 unique compounds with toxicity against the cancer cells.

The challenge, however, is standardization. Organoid heterogeneity, assay reproducibility, and limited publicly available protocols remain persistent barriers to broader adoption.

2. Next-Generation Biosensors: Expanding the Range of Detectable Analytes

Central to HTS are biosensors and assays that translate biochemical activities into measurable signals. Despite advances in automation infrastructure, the limited availability of robust biosensors and difficulty integrating them with ultra-HTS platforms remains a major bottleneck.

Recent progress has focused on expanding the repertoire of biosensor types:

Transcription Factor-Based Biosensors

Whole-cell transcription factor (TF) biosensors have been successfully integrated into high-throughput platforms. In one demonstration, an Escherichia coli TF-based biosensor enabled screening of approximately 50,000 mutants per library when integrated with a FADS platform for co-cultivation with Saccharopolyspora erythraea. In Bacillus subtilis, a TF-based biosensor detected glucosamine and enabled screening of approximately 0.2 million enzyme variants.

GPCR-Based Biosensors

G protein-coupled receptor (GPCR) biosensors detect extracellular molecules through cell-surface signaling, making them suitable for drug-related compounds such as cannabinoids and opioids. Recent efforts have engineered minimal yeast strains with non-essential GPCR-related genes deleted to improve detection sensitivity. However, most screenings remain restricted to well-plate formats with throughput limits of 10²–10⁴ variants per experiment. Microdroplet-based systems coupled with FACS have enabled larger libraries (10⁶–10⁷) to be screened in single experiments.

Aptamer-Based Biosensors

DNA and RNA aptamers offer simple design, easy modification, fast response, and strong multiplexing capability. Fluorescent structure-switching aptamer designs are particularly well-suited for in vitro HTS of enzyme activities or extracellular products.

Medical Journal IMJ Health Call for Papers

3. Label-Free and Real-Time Screening Technologies

Traditional HTS relies heavily on labeled substrates or reporter systems, which can introduce artifacts and limit the range of measurable interactions. Label-free technologies are gaining traction for their ability to measure native biological processes in real time.

Impedance-Based GPCR Screening

A 2026 platform for label-free GPCR ligand identification uses impedance-based real-time cellular analysis. This approach detects cellular responses to receptor activation without requiring fluorescent or radioactive labels, enabling kinetic screening of ligand-receptor interactions as they occur.

Multiplexed Proteomic Biosensors

A 2025 study in Communications Biology described a multiplexed proteomic biosensor platform for label-free real-time kinetic screening of thousands of protein interactions. This technology enables simultaneous monitoring of binding events across diverse protein targets, with applications ranging from antibody characterization to viral variant binding studies.

4. 3D Cardiac Microtissues: Industrializing Safety Screening

Cardiotoxicity remains a leading cause of drug attrition. Traditional cardiac safety assays often use 2D cardiomyocyte cultures that poorly predict clinical arrhythmia risk.

A 2025 study demonstrated the industrialization of 3D hiPSC-derived cardiac microtissues for high-throughput cardiac safety and drug discovery screening. Key achievements include:

  • Scalable, scaffold-free generation from cryopreserved batches of hiPSC-cardiomyocytes, endothelial cells, and fibroblasts
  • Automated formation and maintenance using robotics
  • Fluorescence-based calcium and voltage assays for evaluating cardiac safety and efficacy
  • Screening of more than 2,000 compounds from a drug repurposing library, demonstrating scalability

The platform accurately reflected known responses to cardioactive drugs and identified 17 compounds that rescued an arrhythmic phenotype associated with CPVT1. This work represents a significant step toward regulatory acceptance of 3D cardiac models for safety assessment.

5. AI and Machine Learning in HTS Analysis

The massive datasets generated by HTS campaigns increasingly require AI-driven approaches for analysis and interpretation.

Low-Replicate Screening with Machine Learning

A 2025 study in the European Journal of Pharmacology demonstrated that machine learning enables high-throughput, low-replicate screening for anti-seizure compounds using larval zebrafish. By combining locomotor and calcium fluorescence data, researchers developed classifiers that distinguished seizure-like activity with high accuracy (AUC-ROC: 0.98). Notably, the approach enabled reliable detection of anti-seizure medication effects with as few as N = 4 replicates—a significant reduction from conventional screening requirements.

Biosensor-Enabled Machine Learning

The integration of biosensor-enabled HTS with machine learning is accelerating biocatalyst engineering. Biosensors generate rich datasets that can train models to predict enzyme function, guide library design, and prioritize variants for experimental validation.

6. Automation Platforms and Collaborative Innovations

The complexity of modern bioassays has driven innovation in automation platforms and collaborative approaches.

Miniaturized, High-Throughput Assays

At SLAS2026, SPT Labtech and BellBrook Labs announced a collaboration to develop a miniaturized, high-throughput cell-based assay for VPS4B ATPase inhibitors. The platform combines BellBrook's Transcreener ADP2 fluorescence polarization assay with SPT Labtech's dragonfly liquid handling system, operating in 384- and 1536-well formats. The collaboration successfully identified 13 novel VPS4B inhibitors.

Reproducibility Through Automation

Charles River Laboratories and Synthace announced a collaboration to advance assay development using design of experiments (DoE) and automation. A proof-of-concept project implemented over 700 experimental conditions across multiple laboratories, demonstrating improved reproducibility and reduced time for robust assay development.

New Discovery Platforms

Revvity launched multiple platforms at SLAS2026, including the Opera Phenix OptIQ high-content screening system (with 95% peak camera quantum efficiency for improved sensitivity) and the EnVision Nexus One multimode plate reader, designed to streamline high-throughput workflows.

7. Novel Model Organisms and Assay Formats

Innovation in HTS extends beyond traditional cell-based assays to include whole-organism screening platforms.

C. elegans In Vivo Screening

Magnitude Biosciences secured $1.72 million to scale its VivoScan platform, which uses Caenorhabditis elegans populations for in vivo high-throughput screening. The platform combines automated handling, robotics, advanced imaging, and machine learning to capture multi-parametric phenotypic readouts across a living system. The company aims to build a framework capable of screening millions of compounds within a whole organism.

Zebrafish Embryonic Photomotor Response

A multi-camera array microscope (Kestrel) enables enhanced high-throughput embryonic photomotor response assays in zebrafish. The system provides comprehensive plate imaging at 9.6 µm resolution with 10+ Hz video capture across 96-well plates, enabling detection of concentration-dependent responses to compounds without requiring dechorionation.

Euglena gracilis for Antibacterial Screening

A novel one-step, cost-effective assay uses Euglena gracilis to screen for antibacterial activity by detecting compound-induced bleaching—a phenomenon linked to antibiotics that inhibit DNA or protein synthesis. The assay identifies compounds with potential antibacterial activity that are likely non-toxic to eukaryotes.

8. Key Challenges and Future Directions

Despite rapid progress, several challenges remain:

Standardization and Reproducibility

Organoid heterogeneity, assay protocol variability, and limited publicly available protocols constrain broader adoption. The reproducibility crisis in preclinical research—estimated to cost $100 billion annually—highlights the need for more robust assay development methodologies.

Integration with Automation

Integrating diverse biosensor types with HTS platforms, particularly ultra-HTS, remains difficult. The gap between biosensor availability and HTS infrastructure limits the range of screenable targets.

Validation and Translation

Most organoid-based HTS studies demonstrate feasibility but lack in vivo validation. More systematic validation across multiple organoid lines and animal models is required to facilitate robust preclinical evaluation.

Cost and Accessibility

Advanced HTS platforms require significant capital investment, specialized expertise, and ongoing maintenance. Democratizing access to these technologies remains a challenge for smaller research groups and institutions in resource-limited settings.

Automated bioassay development and high-throughput screening are undergoing a transformative period. The field is moving beyond simple, reductionist assays toward more physiologically relevant 3D models, label-free detection technologies, and AI-driven analysis.

The emergence of patient-derived organoids, 3D cardiac microtissues, and whole-organism screening platforms is expanding the range of biology that can be interrogated at scale. Advances in biosensor technology—including transcription factor, GPCR, and aptamer-based sensors—are broadening the repertoire of detectable analytes and enabling integration with ultra-HTS workflows.

Collaborations between automation providers and assay developers are accelerating the translation of these technologies into practical screening solutions. New platforms launched at SLAS2026 demonstrate continued investment in high-content imaging, multiplexed detection, and intelligent automation.

However, challenges remain. Standardization, reproducibility, validation, and cost continue to limit broader adoption. Addressing these challenges will require continued innovation in assay design, automation, and data analysis—along with collaborative efforts to establish best practices and share protocols.

For researchers and drug discovery teams, the tools available for automated bioassay development are becoming more sophisticated and more accessible. Those who embrace these technologies will be better positioned to identify promising drug candidates faster and with greater confidence in their translational potential. For those considering doctoral research in this area, Top 10 Pharmaceutical Research Topics for PhD offers guidance on selecting impactful research directions.

Continue Exploring Our Blog